Loading...
Loading...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR. Spoken Alpha tracks SKBBY's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks SKBBY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SKBBY.
curl https://api.spokenalpha.com/v1/companies/SKBBY| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.12 | $3.59 | +14.7% | +2.9% | +1.8% |
| Q4 FY2026 | $4.15 | $3.51 | +18.1% | +0.6% | +2.8% |
| Q3 FY2026 | $4.31 | $3.59 | +20.0% | +3.1% | +5.3% |
| Q2 FY2026 | $4.14 | $3.65 | +13.3% | -3.5% | -2.2% |
| Q1 FY2025 | $4.14 | $3.80 | +8.9% | -7.7% | -8.7% |
| Q4 FY2025 | $4.07 | $3.60 | +13.1% | +2.7% | +2.5% |
| Q3 FY2025 | $4.17 | $3.57 | +16.8% | -0.8% | -0.1% |
| Q2 FY2025 | $4.53 | $3.68 | +23.1% | -7.2% | -4.7% |
| Q1 FY2024 | $4.18 | $3.73 | +12.0% | +1.3% | +1.3% |
| Q4 FY2024 | $4.19 | $3.68 | +13.8% | +2.1% | -0.5% |